Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease

Clin Adv Hematol Oncol. 2003 Dec;1(12):741-2; discussion 743.

Authors

Steven C Cunningham¹, Mike Cusnir, Richard K Burdick, David A Van Echo, Robert Moesinger

Affiliation

¹ University of Maryland Medical System, Baltimore, MD 21201, USA.

PMID: 16258479

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / pathology
Adenocarcinoma / radiotherapy
Adenocarcinoma / secondary
Adenocarcinoma / surgery
Adenocarcinoma / therapy*
Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Back Pain / etiology
Capecitabine
Clinical Trials as Topic / statistics & numerical data
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Docetaxel
Female
Fluorouracil / administration & dosage
Fluorouracil / analogs & derivatives
Fluorouracil / therapeutic use
Gemcitabine
Humans
Liver Neoplasms / secondary
Middle Aged
Neoadjuvant Therapy*
Neoplasm Invasiveness
Pancreatectomy*
Pancreatic Neoplasms / drug therapy
Pancreatic Neoplasms / pathology
Pancreatic Neoplasms / radiotherapy
Pancreatic Neoplasms / surgery
Pancreatic Neoplasms / therapy*
Splenectomy
Taxoids / administration & dosage
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Taxoids
Deoxycytidine
Docetaxel
Capecitabine
Fluorouracil
Gemcitabine